1. Home
  2. ALLT vs FULC Comparison

ALLT vs FULC Comparison

Compare ALLT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allot Ltd.

ALLT

Allot Ltd.

HOLD

Current Price

$7.07

Market Cap

519.6M

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$8.00

Market Cap

462.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLT
FULC
Founded
1996
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
519.6M
462.2M
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
ALLT
FULC
Price
$7.07
$8.00
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
$12.40
$16.38
AVG Volume (30 Days)
344.2K
1.0M
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.84
N/A
Revenue Next Year
$12.08
N/A
P/E Ratio
$469.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.37
$2.32
52 Week High
$11.92
$15.74

Technical Indicators

Market Signals
Indicator
ALLT
FULC
Relative Strength Index (RSI) 50.11 52.75
Support Level $6.20 $6.33
Resistance Level $8.20 $8.17
Average True Range (ATR) 0.29 0.49
MACD 0.17 0.19
Stochastic Oscillator 100.00 95.73

Price Performance

Historical Comparison
ALLT
FULC

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: